• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

B2

B2 (Linazolamide intermediate B impurity 2) 促进亨廷顿病和帕金森病细胞模型中的包涵体形成。

CAS号

115687-05-3

分子式

C20H17ClN4O3

主要靶点

Others|Sirtuin

仅限科研使用

Cat No : CM08639

Print datasheet

Synonyms

CPNQ|Linazolamide intermediate B impurity 2|奥司他韦杂质B(2-叠氮杂合物)|5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline

验证数据展示

  • CAS No.: 115687-05-3

    B2
    CAS#: 115687-05-3

产品信息

B2 promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease

CAS号 115687-05-3
分子式 C20H17ClN4O3
主要靶点 Others|Sirtuin
主要通路 表观遗传|DNA损伤和修复|其他
分子量 396.83
纯度 99.14%， 此纯度可做参考，具体纯度与批次有关系，可咨询客服
储存条件 Powder: -20°C for 3 years | In solvent: -80°C for 1 year
别名 CPNQ|Linazolamide intermediate B impurity 2|奥司他韦杂质B(2-叠氮杂合物)|5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline

溶解度

Ethanol:<1 mg/mL,H2O:2 mg/mL,DMSO:<39.68mg/ml

参考文献

1.Bodner et al (2006) Pharmacological promotion of inclusion formation:a therapeutic approach for Huntington's and Parksinson's diseases. Proc.Natl.Acad.Sci.USA 103 4246

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2